Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Swiss Regulator Accepts Edaravone for ALS: Mitsubishi Tanabe
January 24, 2018
- Miraca Inks Exclusive Service Accord with Myriad for Lynparza CDx
January 24, 2018
- Opdivo Earns Gastric Cancer Nod in Taiwan
January 24, 2018
- Adcetris Adds CTCL Indication in Europe
January 24, 2018
- Gilteritinib Grabs EU Orphan Status for AML: Astellas
January 24, 2018
- Biogen Japan to Kick Off PIII Study for Stroke Drug by Year-End
January 24, 2018
- Mitsubishi Tanabe Withdraws Patent Infringement Lawsuit over Radicut Bag against Nissin Pharmaceutical
January 24, 2018
- AnGes’ Gene Therapy Re-Submitted for CLI, This Time for Conditional Approval
January 23, 2018
- Astellas/Vical’s CMV Vaccine Flops in Global PIII
January 23, 2018
- MSD Files for Once-Daily Isentress in Japan
January 23, 2018
- Huahai’s Japan Arm to Focus on Sales of API, Contract Manufacturing; Planning Sales of In-House Products in 10 Years
January 23, 2018
- Eisai Grants Rights for Cancer Agent E7046 to Chinese Immunotherapy Firm
January 22, 2018
- Mochida’s Enbrel Biosimilar Approved, with Ayumi as Distributor
January 22, 2018
- US Court Rejects Eisai Partner’s Bid for Rehearing on Aloxi Decision
January 19, 2018
- NanoCarrier in Talks for Biz Alliance with Ceolia
January 19, 2018
- Industry Expresses Disappointment about “Expansion” of Essential Drugs; Some Looking to Real Expansion in FY2020
January 19, 2018
- Japan Units of Shire, Baxalta to Merge on Feb. 1
January 19, 2018
- Another Drug Lag “Will” Arise, Says Mitsubishi Tanabe President after JPMA Chief’s Denial
January 19, 2018
- Novartis to Transfer Rasilez to OrphanPacific in Japan
January 18, 2018
- Kissei/JCR’s Nesp Biosimilar Shows Equivalence in Japan PIII
January 18, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…